Viracta Therapeutics
Viracta Therapeutics
VIRX
NASDAQ
0.03
USD
50.00%
About
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val).
Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors.
The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 627.0K |
| Three Month Average Volume | 12.6M |
| High Low | |
| Fifty-Two Week High | 1.5151 USD |
| Fifty-Two Week Low | 0.202 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 27 Aug 2024 |
| Price and Volume | |
| Current Price | 0.2136 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -54.46% |
| Thirteen Week Relative Price Change | -71.49% |
| Twenty-Six Week Relative Price Change | -78.65% |
| Fifty-Two Week Relative Price Change | -88.16% |
| Year-to-Date Relative Price Change | -68.36% |
| Price Change | |
| One Day Price Change | -4.17% |
| Thirteen Week Price Change | -69.49% |
| Twenty-Six Week Price Change | -76.53% |
| Five Day Price Change | -24.20% |
| Fifty-Two Week Price Change | -85.17% |
| Year-to-Date Price Change | -62.53% |
| Month-to-Date Price Change | -55.41% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.46859 USD |
| Book Value Per Share (Most Recent Quarter) | 0.06776 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.46859 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.06776 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.25589 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.32191 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.16247 USD |
| Normalized (Last Fiscal Year) | -1.32191 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.32191 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.16247 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.32191 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.16247 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.3734 USD |
| Cash Per Share (Most Recent Quarter) | 0.76122 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.30917 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.14923 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.97787 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -6,305 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -11,853.94% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -11,896.58% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -11,853.94% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -33.96% |
| Tangible Book Value (5 Year) | 35.62% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | 27.86% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 22.95% |
| EPS Change (Trailing Twelve Months) | 15.84% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -11,259,000 |
| Net Debt (Last Fiscal Year) | -28,417,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -40,030,000 |
| Free Cash Flow (Trailing Twelve Months) | -38,187,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -141 |
| Net Interest Coverage (Trailing Twelve Months) | -60 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 138 |
| Total Debt to Equity (Most Recent Quarter) | 702 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -66.88% |
| Return on Assets (Trailing Twelve Months) | -83.82% |
| Return on Assets (5 Year) | -86.35% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -149.04% |
| Return on Equity (Trailing Twelve Months) | -278.57% |
| Return on Equity (5 Year) | -150.55% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -97.91% |
| Return on Investment (Trailing Twelve Months) | -140.98% |
| Return on Investment (5 Year) | -106.38% |